COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

RSS Feeds

RSS Feeds

RSS (Really Simple Syndication) feeds provide an easy way to keep up with news and information about our company. Most web browsers have built-in RSS readers, or you can use our feeds in an RSS reader or aggregator.

Latest News Releases

Latest SEC Filings

Recent Events

Investor Presentation

More information is coming soon.


Recent BDSI News

BioDelivery Sciences Reports Second Quarter 2021 Results August 4, 2021

Total Company Net Revenue of $41.4 Million Driven by BELBUCA ® All-Time High TRx Market Share Strong Profitability with GAAP Net Income of $9.1 Million , or $0.09 per share, EBITDA Margin of 32%, and Non-GAAP Net Income of $12.5 Million , or $0.12 per Share, Drives Operating Cash Generation of $9.2 ...

Read more
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine August 4, 2021

The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults First step to building a growth platform in Neurology Patent protection until 2036 RALEIGH, N.C. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , ...

Read more
BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021 July 22, 2021

RALEIGH, N.C. , July 22, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its second quarter 2021 ...

Read more

Upcoming Events

More events are coming soon.

Stay Connected

Stay up to date on the latest news

Get started now
July 9, 2021 /
Data provided by West LLC. Minimum 15 minutes delayed.